J Vaňásek

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Platelet Transfusion Therapy

Michael J. Blaha, Joe Maly, J Vaňásek et al. · JAMA · 1987 · 194 citations

Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

Renato D. Lópes, Celestia S. Higano, Susan F. Slovin et al. · Circulation · 2021 · 141 citations · Full text

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)

Suresh S. Ramalingam, Jeffrey Crawford, Alex Y. Chang et al. · Annals of Oncology · 2013 · 55 citations

Antifibrotic Therapy, Fortis-m Trial, Medicine +9